Clinical Trial Update: A Multiple Tumor Species, Open and Multi-center Clinical Study of Alpaloritovorelli Antibodies (QL-1706) Combined with Pulsed Low Dose Rate External Irradiation (PLDR) for Disease Progression After Previous Anti-tumor Therapy [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update for QL-1706 antibodies combined with pulsed low dose rate external irradiation (PLDR) in patients with cancers, currently not yet …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer
• Esophageal Cancer
• Non-small Cell Lung Cancer

Drugs mentioned

• QL-1706

Snippet

Sponsor: Anhui Provincial Hospital | Conditions: Esophageal Cancer, Non Small Cell Lung Cancer | Phase 1 | Status: NOT_YET_RECRUITING